Break the Silence! World IBD Day 2021
This year, for World IBD Day, EFCCA would like to promote the discussion on IBD and wellbeing.
English
Concluded
IMPACT
The IMPACT survey was a joint project of EFCCA and its national member associations. It was launched in November 2010 and closed in August 2011.
IMPACT II is now on-going in several other countries in and outside Europe.
English
Discover the true effect of anaemia in IBD
The new AEGIS-1, and The new AEGIS-1, and AEGIS-2 studies are aiming to find out whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in non-active ulcerative colitis (UC), and non-active Crohn’s disease (CD).
Summary
English
World Symposium on IBD research funded by IBD patient associations
World Symposium on IBD Research funded by IBD patients associations
Global alliance against IBD
On 18 October 2012, the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) met in Brussels with worldwide patient associations for the first ever World Symposium on IBD research funded or promoted by IBD patients' associations.
English
Discover the true effect of anaemia in IBD
As many of us unfortunately know, fatigue is said to be one of the ‘big three’ symptoms of IBD (pain, fatigue, and urgently needing the toilet).
As several important articles note that anaemia may be especially significant in people with IBD, EFCCA, supported by Vifor Pharmaceuticals and A+A Research, are currently carrying out a survey to understand:
-
The effects of anaemia in IBD from the patient’s perspective
-
The effect of fatigue on a variety of activities in daily life
English
Innovative medicines - Mapping project
Innovative medicines - EU mapping project
English
Clinical Research Study
The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective in reducing the severity of the symptoms to the point of remission in individuals with moderate to severe ulcerative colitis or Crohn’s disease when compared to placebo. The secondary objective is to evaluate if the investigational medicine being studied is effective in sustaining disease remission. Remission means absence or sustained reduction of symptoms.
Study participants must be:
English
Join the Fight Against IBD Project 2012
Patient and Medical Associations Leaders from More than 30 Countries Gather in Barcelona to launch the “Join the Fight Against IBD” Initiative
The initiative aims to accelerate the disease burden recognition and to optimize standards of care for patients with IBD
English
Join the Fight Against IBD 2013
The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) and the European Crohn’s and Colitis Organisation (ECCO) have initiated the public awareness campaign “Join the fight against IBD”. Its aim is to enhance the general understanding of the physical and socio-economic burdens of the disease and to accelerate the dissemination of new standards of care of inflammatory bowel diseases (IBD) among health institutions, healthcare providers.
English
From EU citizenship to IBD-zenship 2013
Conference at the European Parliament, 17 October 2013
“Equal Rights for Citizens with IBD” was the main message emerging from the conference organized by EFCCA in cooperation with the European Crohn’s and Colitis Organisation (ECCO) and United European Gastroenterologists (UEG) which took place in the European Parliament on 17 October.
English